Human Longevity, Inc., and Freedom Acquisition 1 announce their intention to combine

SAN DIEGO & LONDON–(BUSINESS WIRE)–Human Longevity, Inc. (“HLI”), built by the pioneers of the human genome sequencing effort, and Freedom Acquisition I Corporation (“Freedom”) (NYSE: FACT), a publicly traded special purpose acquisition company, announced today that they have signed a non-binding letter of intent (the “Letter of Intent”) for a proposed business combination that would result in HLI becoming a publicly listed company. Upon the closing of the transaction, the combined company wo
Click here to view original post